Concepedia

Publication | Open Access

Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

DOIFull Paper Access

383

Citations

22

References

2014

Year

Hans‐Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Uli C. Broedl, Hans J. Woerle
Diabetes Care

Abstract

Empagliflozin 10 and 25 mg for 24 weeks as add-on to metformin therapy significantly improved glycemic control, weight, and BP, and were well-tolerated.

References

YearCitations

Page 1